Investing in SciSparc: Tel Aviv Biotech’s Rise in Cannabinoid CNS Treatments
Explore how SciSparc Ltd. is pioneering cannabinoid tech for CNS disorders—its market dynamics, stock trends, and global impact in biotech.
2 minutes to read
SciSparc Ltd
SciSparc’s Bold Move: Acquiring Endoscopy Patents to Turbo‑Boost CNS Therapy
How SciSparc’s patent‑treasury buy‑out could pivot its Nasdaq stock from niche cannabinoid research to high‑impact CNS endoscopy tech—and what that means for investors.
3 minutes to read
SciSparc Ltd. Shares Surge Amid Merger Delay with AutoMax Motors
SciSparc Ltd. (SPRC) stock experienced a 130% price surge due to a merger-related rally, with investors viewing a delay in the merger with AutoMax Motors as a positive development for the company’s growth prospects.
2 minutes to read